completed2025-05-01D series

Eplontersen

Hereditäre Transthyretin-Amyloidose mit Polyneuropathie (Stadium 1 oder 2

Open official case page ↗

Brand: Wainzua
Manufacturer: AstraZeneca GmbH

G-BA action

final resolution

2026-01-13

Arzneimittel-Richtlinie/Anlage XII: Eplontersen (Hereditäre Transthyretin-Amyloidose mit Polyneuropathie (Stadium 1 oder 2)) – Therapiekosten

Evidence-checked summary

The G-BA issued a final resolution on 2026-01-13. The official page states that it took effect as follows: 15.01.2026. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.

Open G-BA decision →Open official action source ↗

Final benefit result

G-BA result by patient group

Open decision 7472 →

Patient group

Erwachsene mit hereditärer Transthyretin-Amyloidose mit Polyneuropathie der Stadien 1 oder 2

Added benefit not proven

Comparator
Vutrisiran

Open official result PDF ↗

Official case record

What happened, in source order

No inferred stages

Consultation record

Oral hearing and Wortprotokoll

1 hearing

2025-09-08

19 parsed turns

Oral hearing: Eplontersen (Hereditäre Transthyretin-Amyloidose mit Polyneuropathie (Stadium 1 oder 2))

Official Wortprotokoll · 8 pages

Open official source PDF ↗Read transcript turns →

IQWiG comparison

Assessment record versus G-BA action

1 reference

IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.

A25-52

matched

Eplontersen (hereditary transthyretin amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code

Official assessment PDF · 46 pages

Open structured assessment →Open official PDF ↗

G-BA decisions

Distinct actions and documents

2 decision

2025-10-16

final resolution

Arzneimittel-Richtlinie/Anlage XII: Eplontersen (Hereditäre Transthyretin-Amyloidose mit Polyneuropathie (Stadium 1 oder 2))

The G-BA found no proven added benefit for Erwachsene mit hereditärer Transthyretin-Amyloidose mit Polyneuropathie der Stadien 1 oder 2. The appropriate comparator was Vutrisiran. The G-BA issued a final resolution on 2025-10-16. The official page states that it took effect as follows: 16.10.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

4 official documents · 4 cited claims

Open decision →

2026-01-13

final resolution